Skip to main content
All lobbying filings

FORBES-TATE

Lobbying for REVANGENIX · Biopharmaceutical innovator.

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $50,000.00 income · posted Jan 18, 2026

Official filing document

 Lobbying activity 1
Health Issues

Issues related to biopharmaceutical research and innovation.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem